Pivotal phase III trial of oxycodone controlled release [Rexista] in patients with chronic low back pain
Phase of Trial: Phase III
Latest Information Update: 09 Oct 2015
Price : $35 *
At a glance
- Drugs Oxycodone (Primary)
- Indications Back pain
- Focus Registrational; Therapeutic Use
- 09 Oct 2015 According to Intellipharmaceutics media release, the company plans to complete the filing of NDA for Rexista Oxycodone XR (Abuse Deterrent oxycodone hydrochloride) extended release tablets with the FDA in the first half of 2016.
- 30 Mar 2015 Intellipharmaceutics recently filed an IND to the FDA for Rexista, according to a media release.
- 17 Jul 2013 New trial record